[PDF][PDF] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
RA Burger, MW Sill, BJ Monk, BE Greer… - Journal of clinical …, 2007 - researchgate.net
RA Burger, MW Sill, BJ Monk, BE Greer, JI Sorosky
Journal of clinical oncology, 2007•researchgate.netPurpose Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor
progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We
conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab,
an anti-VEGF monoclonal antibody.
progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We
conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab,
an anti-VEGF monoclonal antibody.
Purpose
Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody.
researchgate.net